Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA OKs dosing schedule for GSK vaccine
The approval means Twinrix, the only hepatitis A and hepatitis B combination vaccine available in the US, is now available on a dosing schedule that consists of three
The approval means Twinrix, the only hepatitis A and hepatitis B combination vaccine available in the US, is now available on a dosing schedule that consists of three
<p>THP, a California-based company with a subsidiary in Germany, is focused on research in human antibody technologies. The company has developed a unique transgenic mammalian platform to create
<p>Celebrex is part of a class of drugs known as non-steroidal anti-inflammatory drugs and is similar to ibuprofen and naproxen. The drugs are associated with an increased risk
<p>The transfer will be implemented in conformity with local regulatory requirements and the transfer is expected to occur by October 1, 2007.<br /><br />Given their long-standing relationship, both
The trial will examine four doses of subcutaneous (SC) Belerofon, which will be compared to SC administered IntronA, manufactured by Schering-Plough and Pegasys, manufactured by Roche. The primary
Psoriasis is a non-contagious, chronic autoimmune disease that causes the body to attack itself and create raised, inflamed, scaly, red skin lesions known as plaques, which may crack
The indication for which the company seeks approval is for both monotherapy and for combination treatment with Roche's chemotherapy drug Xeloda. The drug will be used in patients
The product known as Janumet is designed to make it easier for type 2 diabetes patients to control their blood pressure and will treat all causes of the
The study showed a clinically efficacious response to treatment in nearly half of the treated patients. In addition, the product demonstrated an excellent safety profile, with no significant
This action has been taken after Novartis notified the FDA about a retrospective analysis of data from more than 18,000 patients in the clinical trial database. The analysis